KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Interest Expenses (2017 - 2025)

Regeneron Pharmaceuticals (REGN) has 16 years of Interest Expenses data on record, last reported at $12.2 million in Q4 2025.

  • For Q4 2025, Interest Expenses rose 16.19% year-over-year to $12.2 million; the TTM value through Dec 2025 reached $43.8 million, down 20.65%, while the annual FY2025 figure was $43.8 million, 20.65% down from the prior year.
  • Interest Expenses reached $12.2 million in Q4 2025 per REGN's latest filing, down from $19.3 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $19.3 million in Q3 2025 and bottomed at $3.6 million in Q2 2025.
  • Average Interest Expenses over 5 years is $14.4 million, with a median of $14.6 million recorded in 2021.
  • Peak YoY movement for Interest Expenses: surged 139.34% in 2021, then crashed 75.68% in 2025.
  • A 5-year view of Interest Expenses shows it stood at $14.2 million in 2021, then grew by 22.54% to $17.4 million in 2022, then grew by 5.17% to $18.3 million in 2023, then crashed by 42.62% to $10.5 million in 2024, then rose by 16.19% to $12.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $12.2 million in Q4 2025, $19.3 million in Q3 2025, and $3.6 million in Q2 2025.